JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript